Posted by Michael Wonder on 04 Aug 2017
Pancreatic cancer patients to have routine access to life extending drug after new deal, says NICE
4 August 2017 - NICE has recommended nab-paclitaxel for routine NHS use after the company agreed a confidential price discount and provided more evidence on its effectiveness.
Nab-paclitaxel, also known as Abraxane, made by Celgene will be routinely available as an option for patients with pancreatic cancer that has progressed.
When Abraxane is added to a standard chemotherapy, called gemcitabine the evidence has found it extends life by an average of 2.4 months.
